XTL Biopharmaceuticals Ltd. (XTLB)
| Market Cap | 10.88M |
| Revenue (ttm) | 46,000 |
| Net Income (ttm) | -1.06M |
| Shares Out | 881.39M |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 397 |
| Open | 1.310 |
| Previous Close | 1.270 |
| Day's Range | 1.310 - 1.310 |
| 52-Week Range | 0.920 - 3.150 |
| Beta | 1.01 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 19, 2025 |
About XTLB
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and change... [Read more]
Financial Performance
Financial StatementsNews
XTL Names Mr. Noam Band as its New Chief Executive Officer
Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”) announ...
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Completed a Private Placement of $1.5 ...
XTL Entered Definitive Agreement to Acquire The Social Proxy
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Plac...
XTL To Aquire The Social Proxy
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Place...
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel
Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets co...
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets co...
Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual Meeting
JERUSALEM, Sept. 20, 2021 /PRNewswire/ -- Dr. Morris C.